Matrix metalloproteinases and skeletal muscle: A brief review

Muscle and Nerve

Volumn 29, Issue 2, 2004, Pages 191-197

  Carmeli, Eli ^a   Moas, Miri ^a   Reznick, Abraham Z ^b   Coleman, Raymond ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Extracellular matrix; Inflammatory myopathies; Matrix metalloproteinases; Muscle injury skeletal muscle

Indexed keywords

COLLAGEN TYPE 4; CORTICOSTEROID; DEXAMETHASONE; GELATINASE A; GELATINASE B; GLUCOCORTICOID; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL TRIAL; GENE CONTROL; GENE REPRESSION; HOMEOSTASIS; HUMAN; MUSCLE ATROPHY; MUSCLE DENERVATION; MUSCLE DEVELOPMENT; MUSCLE DISEASE; MUSCLE INJURY; MUSCLE ISCHEMIA; MUSCLE NECROSIS; MUSCLE REGENERATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPERFUSION; SHORT SURVEY; SKELETAL MUSCLE; UPREGULATION;

ANIMALS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 0842326021     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10529     Document Type: Short Survey

References (43)

1. Balcerzak D, Querengesser L, Dixon WT, Baracos VE. 2001. Coordinate expression of matrix degrading proteinases and their activators and inhibitors in bovine skeletal muscle. J Anim Sci 2001;79:94-107.
2. Better OS, Rubinstein I. Muscle crush syndrome: pathogenesis and management of casualties. In: Preedy VR, Peters TJ, editors. Skeletal muscle: pathology, diagnosis and management of disease. London: Greenwich Medical Media; 2002. p 37-48.
3. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1993;7:728-735
4. Chin JR, Werb Z. Matrix metalloproteinases regulate morphogenesis, migration, and remodeling of epithelium, tongue skeletal muscle and cartilage in the mandibular arch. Development 1997;124:1519-1530.
5. Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000;54:65-71
6. Choi HR, Kondo S, Hirose K, Ishiguro N, Hasegawa Y, Iwata H. Expression and enzymatic activity of MMP-2 during healing process of the acute supraspinatus tendon tear in rabbits. J Orthop Res 2002;20:927-933.
7. El Fahime E, Torrente Y, Caron NJ, Bresolin MD, Tremblay JP. In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity. Exp Cell Res 2000;258:279-287.
8. Ennis BW, Matrisian LM. Matrix degrading metalloproteinases. J Neurooncol 1994;18:105-109.
9. Frisch SM, Morisaki JH. Positive and negative transcriptional elements of the human type IV collagenase gene. Mol Cell Biol 1990;10:6524-6532.
10. Frisdal E, Teiger E, Lefaucheur JP, Adnot S, Planus E, Lafuma C, D'ortho MP. Increased expression of gelatinases and alteration of basement membrane in rat soleus muscle following femoral artery ligation. Neuropathol Appl Neurobiol 2000;26:11-21.
11. Guerin CW, Holland PC. Synthesis and secretion of matrix degrading metalloproteinases by human skeletal muscle satellite cells. Dev Dyn 1995;202:91-99.
12. Gutierrez JM, Rucavado A. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage. Biochimie 2000;82:841-850.
13. Haas TL, Milkiewicz M, Davis SJ, Zhou AL, Egginton S, Brown MD, Madri JA, Hudlicka O. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 2000;279:H1540-1547.
14. Haas TL. Molecular control of capillary growth in skeletal muscle. Can J Appl Physiol 2002;27:491-515.
15. Harendza S, Pollock AS, Mertens PR, Lovett DH. Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J Biol Chem 1995;270:18786-18796.
16. Kherif S, Dehaupas M, Lafuma C, Fardeau M, Alameddine HS. Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve. Neuropathol Appl Neurobiol 1998;24:309-319.
17. Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, Verdiere-Sahuque M, Fardeau M, Almeddine HS. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol 1999;205:158-170.
18. Kieseier BC, Schneider C, Clements JM, Gearing AJH, Gold R, Toyka KV, Hartung HP. Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 2001;124:341-351.
19. Koskinen SO, Kjaer M, Mohr T, Sorensen FB, Suuronen T, Takala TES. Type IV collagen and its degradation in paralyzed human muscle: effect of functional electrical stimulation. Muscle Nerve 2000;23:580-589.
20. Koskinen SO, Wang W, Ahtikoski AM, Kjaer M, Han XY, Komulainen J, Kovanen V, Takala TES. Acute exercise induced changes in rat skeletal muscle mRNAs and proteins regulating type IV collagen content. Am J Physiol Regul Integr Comp Physiol 2001;280:R1292-1300.
21. Koskinen SO, Hoyhtya M, Turpeenniemi-Hujanen T, Martikkala V, Makinen TT, Oksa J, Rintamaki H, Lofberg M, Somer H, Takala TES. Serum concentrations of collagen degrading enzymes and their inhibitors after downhill running. Scand J Med Sci Sports 2001;11:9-15.
22. Kovanen V, Suominen H, Peltonen L. Effects of aging and life-long physical training on collagen in slow and fast skeletal muscle in rats. A morphometric and immuno-histochemical study. Cell Tissue Res 1987;248:247-255.
23. Lalu MM, Csonka C, Giricz Z, Csont T, Schultz R, Ferdinandy P. Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Commun 2001;296:937-941.
24. Lattanzi G, Muntoni F, Sabatelli P, Squarzoni S, Maraldi NM, Villanova M, Columbaro M, Merlini L, Marmiroli S. Unusual laminin alpha2 processing in myoblasts from patients with a novel variant of congenital muscular dystrophy. Biochem Biophys Res Commun 2000;277:639-642.
25. Lewis MP, Tippett HL, Sinanan AC, Morgan MJ, Hunt NP. Gelatinase-B (matrix metalloproteinase-9; MMP-9) secretion is involved in the migratory phase of human and murine muscle cell cultures. J Muscl Res Cell Motil 2000;21:223-233.
26. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structure, evolution, and diversification. FASEB J 1998;12:1075-1095.
27. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-463.
28. Matrisian LM. Matrix metalloproteinase gene expression. Ann NY Acad Sci 1994;732:42-50.
29. Matrisian LM, Wright J, Newell K, Witty JP. Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 1994;24:152-161.
30. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritis diseases: bull's eye or missing the mark? Arthritis Rheum 2002;46:13-20.
31. Mertens PR, Harendza S, Pollack AS, Lovett DH. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase-2 transcription is mediated by YB-1. J Biol Chem 1997;272:22905-22912.
32. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999;11:614-621.
33. Myllyla R, Salminen A, Peltonen L, Takala TES, Vihko V. Collagen metabolism of mouse skeletal muscle during the repair exercise injuries. Pflugers Arch 1986;407:64-70.
34. Pearson AM, Young RB. Disease and disorders of muscle. Adv Food Nutr Res 1993;37:339-423.
35. Pross C, Farooq MM, Angle N, Lane JS, Cerveira JJ, Xavier AE, Freischlag JA, Law RE, Gelabert HA. Dexamethasone inhibits vascular smooth muscle cell migration modulation of matrix metalloproteinase activity. J Surg Res 2002;102:57-62.
36. Reznick AZ, Menashe O, Bar-Shai M, Coleman R, Carmeli E. Expression of matrix metalloproteinases, inhibitor, and acid phosphatase in muscles of immobilized hindlimbs of rats. Muscle Nerve 2003;27:51-59.
37. Rivilis I, Milkiewicz M, Boyd P, Goldstein J, Brown MD, Egginton S, Hansen FM, Hudlicka O, Hass TL. Differential involvement of MMP-2 and VEGF during muscle stretch-versus shear stress-induced angiogenesis. Am J Physiol Heart Circ Physiol 2002;283:H1430-H1438.
38. Roach DM, Fitridge RA, Laws PE, Millard SH, Varelias A, Cowled PA. Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury: protection by the MMP inhibitor, doxycycline. Eur J Vasc Endovasc Surg 2002;23:260-269.
39. Rucavado A, Escalante T, Teixeira CF, Fernandes CM, Diaz C, Gutierrez JM. Increments in cytokines and matrix metalloproteinases in skeletal muscle after injection of tissue-damaging toxins from venom of the snake Bothrops asper. Mediators Inflamm 2002;11:121-128.
40. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-65.
41. Schoser BG, Blottner D. Matrix metalloproteinases MMP-2, MMP-7, and MMP-9 in denervated human muscle. Neuroreport 1999;10:2795-2797.
42. Schoser BG, Blottner D, Stuerenburg HJ. Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. Acta Neurol Scand 2002;105:309-313.
43. Singh A, Nelson-Moon ZL, Thomas GJ, Hunt NP, Lewis MP. 2000. Identification of matrix metalloproteinases and their tissue inhibitors type 1 and 2 in human masseter muscle. Arch Oral Biol 2000;45:431-440.